MODERATE TO SEVERE PLAQUE PSORIASIS
Clinical trials for MODERATE TO SEVERE PLAQUE PSORIASIS explained in plain language.
Never miss a new study
Get alerted when new MODERATE TO SEVERE PLAQUE PSORIASIS trials appear
Sign up with your email to follow new studies for MODERATE TO SEVERE PLAQUE PSORIASIS, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New psoriasis drug shows promise for teens in early trial
Disease control CompletedThis study tested two doses of bimekizumab, a drug that targets inflammation, in 41 adolescents aged 12 to 17 with moderate to severe plaque psoriasis. The main goals were to measure how the drug behaves in the body and to check its safety. Researchers also looked at how well it …
Matched conditions: MODERATE TO SEVERE PLAQUE PSORIASIS
Phase: PHASE2 • Sponsor: UCB Biopharma SRL • Aim: Disease control
Last updated Jun 27, 2026 12:35 UTC
-
New psoriasis drug shows promise in Head-to-Head trial
Disease control CompletedThis study tested a new medicine called bimekizumab against an existing drug (adalimumab) in 478 adults with moderate to severe plaque psoriasis. The goal was to see if bimekizumab could clear more skin at 16 weeks. Participants received either bimekizumab or adalimumab, and then…
Matched conditions: MODERATE TO SEVERE PLAQUE PSORIASIS
Phase: PHASE3 • Sponsor: UCB Biopharma SRL • Aim: Disease control
Last updated Jun 27, 2026 12:07 UTC
-
New psoriasis drug SHR-1139 enters first human trials
Disease control CompletedThis early-stage trial tests a new drug called SHR-1139 in healthy volunteers and people with moderate-to-severe plaque psoriasis. The main goal is to check safety and how the body handles the drug. A total of 64 participants will receive either the drug or a placebo, with doses …
Matched conditions: MODERATE TO SEVERE PLAQUE PSORIASIS
Phase: PHASE1 • Sponsor: Guangdong Hengrui Pharmaceutical Co., Ltd • Aim: Disease control
Last updated Jun 27, 2026 09:00 UTC
-
New psoriasis drug shows promise in Mid-Stage trial
Symptom relief CompletedThis study tested an experimental drug called SCD-044 in 263 adults with moderate to severe plaque psoriasis. Participants received either the drug or a placebo to see if it could improve skin symptoms like redness and scaling. The main goal was to measure how many people achieve…
Matched conditions: MODERATE TO SEVERE PLAQUE PSORIASIS
Phase: PHASE2 • Sponsor: Sun Pharmaceutical Industries Limited • Aim: Symptom relief
Last updated Jun 27, 2026 08:13 UTC
-
New study reveals how long patients stay on secukinumab for skin and joint conditions
Knowledge-focused CompletedThis completed study followed 127 adults with moderate to severe plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, or non-radiographic axial spondyloarthritis who were already taking or starting secukinumab. Researchers observed them for two years to see how long the…
Matched conditions: MODERATE TO SEVERE PLAQUE PSORIASIS
Sponsor: Novartis Pharmaceuticals • Aim: Knowledge-focused
Last updated Jun 27, 2026 08:00 UTC